Intech Investment Management LLC Has $4.44 Million Stock Position in Glaukos Co. (NYSE:GKOS)

Intech Investment Management LLC lifted its position in Glaukos Co. (NYSE:GKOS) by 44.7% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 29,601 shares of the medical instruments supplier’s stock after purchasing an additional 9,139 shares during the period. Intech Investment Management LLC’s holdings in Glaukos were worth $4,438,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. William Blair Investment Management LLC acquired a new stake in shares of Glaukos in the fourth quarter worth $121,390,000. Cibc World Markets Corp acquired a new stake in shares of Glaukos in the fourth quarter worth $687,000. Corient Private Wealth LLC lifted its stake in shares of Glaukos by 1.1% in the fourth quarter. Corient Private Wealth LLC now owns 30,241 shares of the medical instruments supplier’s stock worth $4,534,000 after buying an additional 341 shares during the last quarter. Picton Mahoney Asset Management acquired a new stake in shares of Glaukos in the fourth quarter worth $125,000. Finally, Commonwealth Equity Services LLC lifted its stake in shares of Glaukos by 12.9% in the fourth quarter. Commonwealth Equity Services LLC now owns 5,770 shares of the medical instruments supplier’s stock worth $865,000 after buying an additional 661 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Trading Down 2.9 %

Shares of Glaukos stock opened at $100.36 on Wednesday. The firm has a market capitalization of $5.68 billion, a PE ratio of -34.97 and a beta of 0.99. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The company’s fifty day moving average price is $138.69 and its two-hundred day moving average price is $137.25. Glaukos Co. has a 52-week low of $85.23 and a 52-week high of $163.71.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The business had revenue of $105.50 million during the quarter, compared to the consensus estimate of $100.72 million. On average, analysts expect that Glaukos Co. will post -1.08 EPS for the current year.

Insider Transactions at Glaukos

In other news, COO Joseph E. Gilliam sold 3,328 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $149.85, for a total value of $498,700.80. Following the sale, the chief operating officer now owns 102,169 shares of the company’s stock, valued at approximately $15,310,024.65. This represents a 3.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Tomas Navratil sold 3,416 shares of the company’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the sale, the insider now directly owns 72,437 shares in the company, valued at approximately $10,658,380.18. The trade was a 4.50 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 16,744 shares of company stock valued at $2,504,131. 6.40% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Mizuho raised shares of Glaukos from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $140.00 to $200.00 in a research report on Wednesday, February 19th. Truist Financial boosted their target price on shares of Glaukos from $152.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Piper Sandler reaffirmed an “overweight” rating and set a $180.00 target price (up previously from $140.00) on shares of Glaukos in a research report on Monday, January 27th. Morgan Stanley lowered shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 target price on the stock. in a research report on Monday, December 2nd. Finally, Needham & Company LLC boosted their target price on shares of Glaukos from $149.00 to $176.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $163.25.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.